The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.
The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of trifunctional anti-CD3 x anti-EpCAM antibody Korjuny (catumaxomab) for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy.
The European Medicine Agency Committee for Medicinal Products for Human Use issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.
Wayne A. I. Frederick, a surgical oncologist and former president of Howard University, will step in as interim chief executive officer of the American Cancer Society, effective Nov. 2.
A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.
Flatiron Health announced a milestone of over 1,000 research publications utilizing Flatiron’s electronic health record-derived real world data.
USC Norris Comprehensive Cancer Center and the University of New Mexico Comprehensive Cancer Centers held the first annual Changing the Face of Cancer Center Leadership Program in June.
Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.
